The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction.
Diastolic dysfunction is an important predictor of poor outcome after myocardial infarction. Metformin treatment improved diastolic function in animal models and patients with diabetes. Whether metformin improves diastolic function in patients presenting with ST-segment elevation myocardial infarcti...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5158040?pdf=render |
id |
doaj-3ae66b98b09c4efda4df17101c21ab1a |
---|---|
record_format |
Article |
spelling |
doaj-3ae66b98b09c4efda4df17101c21ab1a2020-11-25T02:43:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011112e016834010.1371/journal.pone.0168340The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction.Lawien Al AliMinke T HartmanChris P H LexisYoran M HummelErik LipsicJoost P van MelleDirk J van VeldhuisenAdriaan A VoorsIwan C C van der HorstPim van der HarstDiastolic dysfunction is an important predictor of poor outcome after myocardial infarction. Metformin treatment improved diastolic function in animal models and patients with diabetes. Whether metformin improves diastolic function in patients presenting with ST-segment elevation myocardial infarction (STEMI) is unknown.The GIPS-III trial randomized STEMI patients, without known diabetes, to metformin or placebo initiated directly after PCI. The previously reported primary endpoint was left ventricular ejection fraction at 4 months, which was unaffected by metformin treatment. This is a predefined substudy to determine an effect of metformin on diastolic function. For this substudy trans-thoracic echocardiography was performed during hospitalization and after 4 months. Diastolic dysfunction was defined as having the combination of a functional alteration (i.e. decreased tissue velocity: mean of septal e' and lateral e') and a structural alteration (i.e. increased left atrial volume index (LAVI)). In addition, left ventricular mass index and transmitral flow velocity (E) to mean e' ratio (E/e') were measured to determine an effect of metformin on individual echocardiographic markers of diastolic function.In 237 (63%) patients included in the GIPS-III trial diastolic function was measured during hospitalization as well as at 4 months. Diastolic dysfunction was present in 11 (9%) of patients on metformin and 11 (9%) patients on placebo treatment (P = 0.98) during hospitalization. After 4 months 22 (19%) of patients with metformin and 18 (15%) patients with placebo (P = 0.47) had diastolic dysfunction. In addition, metformin did not improve any of the individual echocardiographic markers of diastolic function.In contrast to experimental and observational data, our randomized placebo controlled trial did not suggest a beneficial effect of short-term metformin treatment on diastolic function in STEMI patients.http://europepmc.org/articles/PMC5158040?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lawien Al Ali Minke T Hartman Chris P H Lexis Yoran M Hummel Erik Lipsic Joost P van Melle Dirk J van Veldhuisen Adriaan A Voors Iwan C C van der Horst Pim van der Harst |
spellingShingle |
Lawien Al Ali Minke T Hartman Chris P H Lexis Yoran M Hummel Erik Lipsic Joost P van Melle Dirk J van Veldhuisen Adriaan A Voors Iwan C C van der Horst Pim van der Harst The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. PLoS ONE |
author_facet |
Lawien Al Ali Minke T Hartman Chris P H Lexis Yoran M Hummel Erik Lipsic Joost P van Melle Dirk J van Veldhuisen Adriaan A Voors Iwan C C van der Horst Pim van der Harst |
author_sort |
Lawien Al Ali |
title |
The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. |
title_short |
The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. |
title_full |
The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. |
title_fullStr |
The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. |
title_full_unstemmed |
The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. |
title_sort |
effect of metformin on diastolic function in patients presenting with st-elevation myocardial infarction. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
Diastolic dysfunction is an important predictor of poor outcome after myocardial infarction. Metformin treatment improved diastolic function in animal models and patients with diabetes. Whether metformin improves diastolic function in patients presenting with ST-segment elevation myocardial infarction (STEMI) is unknown.The GIPS-III trial randomized STEMI patients, without known diabetes, to metformin or placebo initiated directly after PCI. The previously reported primary endpoint was left ventricular ejection fraction at 4 months, which was unaffected by metformin treatment. This is a predefined substudy to determine an effect of metformin on diastolic function. For this substudy trans-thoracic echocardiography was performed during hospitalization and after 4 months. Diastolic dysfunction was defined as having the combination of a functional alteration (i.e. decreased tissue velocity: mean of septal e' and lateral e') and a structural alteration (i.e. increased left atrial volume index (LAVI)). In addition, left ventricular mass index and transmitral flow velocity (E) to mean e' ratio (E/e') were measured to determine an effect of metformin on individual echocardiographic markers of diastolic function.In 237 (63%) patients included in the GIPS-III trial diastolic function was measured during hospitalization as well as at 4 months. Diastolic dysfunction was present in 11 (9%) of patients on metformin and 11 (9%) patients on placebo treatment (P = 0.98) during hospitalization. After 4 months 22 (19%) of patients with metformin and 18 (15%) patients with placebo (P = 0.47) had diastolic dysfunction. In addition, metformin did not improve any of the individual echocardiographic markers of diastolic function.In contrast to experimental and observational data, our randomized placebo controlled trial did not suggest a beneficial effect of short-term metformin treatment on diastolic function in STEMI patients. |
url |
http://europepmc.org/articles/PMC5158040?pdf=render |
work_keys_str_mv |
AT lawienalali theeffectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT minkethartman theeffectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT chrisphlexis theeffectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT yoranmhummel theeffectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT eriklipsic theeffectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT joostpvanmelle theeffectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT dirkjvanveldhuisen theeffectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT adriaanavoors theeffectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT iwanccvanderhorst theeffectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT pimvanderharst theeffectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT lawienalali effectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT minkethartman effectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT chrisphlexis effectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT yoranmhummel effectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT eriklipsic effectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT joostpvanmelle effectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT dirkjvanveldhuisen effectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT adriaanavoors effectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT iwanccvanderhorst effectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction AT pimvanderharst effectofmetforminondiastolicfunctioninpatientspresentingwithstelevationmyocardialinfarction |
_version_ |
1724771276348719104 |